ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Pediatric rheumatology"

  • Abstract Number: 1294 • ACR Convergence 2025

    Implementation of Pneumococcal Vaccination in Patients with Childhood-Onset Systemic Lupus Erythematous

    Kristina Ciaglia1 and Magan Fosso2, 1UT Southwestern, Children's Medical Center, and Scottish Rite for Children, Dallas, TX, 2UT Southwestern, Dallas, TX

    Background/Purpose: Pneumococcal vaccination is critical in patients with childhood-onset systemic lupus erythematosus (cSLE) due to their immunocompromised status and increased susceptibility to serious infections. Despite…
  • Abstract Number: 1278 • ACR Convergence 2025

    Differences in Patient and Provider Perception of Functional Status in Adolescents with Lupus

    Emily Masi1, Kimberly Rapoza2, Tamar Rubinstein3, Kathy Kenney-Riley4 and Joyce Hui-Yuen5, 1Cohen Children's Medical Center, North New Hyde Park, NY, 2Mercy College, Dobbs Ferry, NY, 3Albert Einstein College of Medicine, White Plains, NY, 4Mercy University, Dobbs Ferry, NY, 5North Shore LIJ Health System, Great Neck, NY

    Background/Purpose: Patient and provider discordance can negatively impact medication adherence and disease outcomes in pediatric lupus. Functional status is known to greatly affect perception of…
  • Abstract Number: 0428 • ACR Convergence 2025

    The OMERACT Juvenile Idiopathic Arthritis MRI Score for Active and Structural Lesions in the Sacroiliac Joints: Development and Validation in Two Longitudinal Cohorts

    Walter P. Maksymowych1, Michael Francavilla2, Nele Herregods3, Robert G. W. Lambert4, Arthur Meyers5, Joel Paschke6, Jennifer Stimec7, Pamela Weiss8 and Dax Rumsey9, 1Department of Medicine, University of Alberta, 568 Heritage Building, Edmonton, AB, Canada, 2Department of Pediatric Radiology, Children’s Hospital Philadelphia, Philadelphia, PA, 3Department of Pediatric Radiology, Ghent University Hospital, Ghent, Belgium, 4University of Alberta, Department of Radiology & Diagnostic Imaging, Edmonton, AB, Canada, 5Department of Radiology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 6CARE Arthritis Limited, Edmonton, AB, Canada, 7Department of Diagnostic Imaging, SickKids, University of Toronto, Toronto, Canada, 8Childrens Hospital of Philadelphia, Philadelphia, PA, 9Department of Pediatrics, University of Alberta, Edmonton, AB, Canada

    Background/Purpose: The OMERACT Juvenile Idiopathic Arthritis MRI (JAMRIS) Working group has defined a spectrum of MRI lesions in the sacroiliac joint (SIJ) in youth with…
  • Abstract Number: 0402 • ACR Convergence 2025

    Risk Factors for Anti-Adalimumab Antibody Development in Pediatric Patients Using Adalimumab for Rheumatic Disease and Associated Conditions

    Dawn Gist1, Andrea Ramirez1, Jamie Lai2, Duc Nguyen1 and Kexin Guo1, 1Baylor College of Medicine, Houston, TX, 2Baylor College of Medicine, The Woodlands, TX

    Background/Purpose: Adalimumab is a monoclonal antibody against TNF-α that is commonly used to treat JIA, hidradenitis suppurativa (HS), chronic uveitis, sarcoidosis, and chronic nonbacterial osteomyelitis…
  • Abstract Number: 0126 • ACR Convergence 2025

    Performance of the 2023 and 2006 APS Classification Criteria in Pediatric Patients Diagnosed with APS: A Multisite Cohort Study

    Jacqueline Madison1, Elizabeth Sloan2, Cristina Saez3, Olivia Kwan4, Kevin Lewis1, Jonathan Marilao5, Blake Baay6, Rasha Elrefai4, Marissa Dale7, Deborah McCurdy8, Jheel Bhatt9, Sasidhar Goteti10, Ekemini Ogbu11, Jason S. Knight1 and Yu (Ray) Zuo1, 1University of Michigan, Ann Arbor, MI, 2UT Southwestern, Children's Medical Center, and Scottish Rite for Children, Dallas, TX, 3Children's Hospital Colorado, Glendale, CO, 4Baylor College of Medicine, Houston, TX, 5University of Texas Southwestern, Dallas, TX, 6Scottish Rite for Children, Dallas, TX, 7Hospital for Special Surgery/NYP Cornell, New York, NY, 8UCLA Medical Center, Los Angeles, CA, 9Advent Health Orlando, Orlando, FL, 10University of Utah, Salt Lake City, UT, 11Cincinnati Children's Hospital Medical Center, Cincinnati, OH

    Background/Purpose: Antiphospholipid syndrome (APS) is a thrombo-inflammatory disorder that causes significant morbidity and mortality, even in children. The 2023 ACR/EULAR classification criteria, which use weighted…
  • Abstract Number: 2537 • ACR Convergence 2025

    Variation in Treatment Approaches in IgA-Vasculitis Among Pediatricians and Pediatric rheumatologists: A Cross-Sectional International Survey

    Merav Heshin Bekenstein1, Tali Elbaz2, Yael Illous2 and Barak Kandell3, 1Tel Aviv Medical Center Israel, Binyamina, Tel Aviv, Israel, 2School of Medicine, Faculty of Medical and Health Sciences, Tel Aviv, Israel, 3The Academic College of Tel Aviv-Yafo, Tel Aviv, Israel

    Background/Purpose: IgA Vasculitis (IgAV) is the most common small-vessel vasculitis in children. Although there is no evidence-based recommendations for treating IgAV, the European SHARE recommendations…
  • Abstract Number: 2154 • ACR Convergence 2025

    Whole-Body MRI Findings in a Cohort of  Children with Chronic Nonbacterial Osteomyelitis

    Mara Rodriguez1, Maurice Davenport Munoz2, Kiery Braithwaite3, Lori Ponder4, Kelly Rouster-Stevens5, Solveig Argeseanu Cunningham6 and Sampath Prahalad7, 1Emory University School of Medicine / Children's Healthcare of Atlanta, Atlanta, GA, 2Emory University School of Medicine, Pediatrics, Atlanta, 3Children's Healthcare of Atlanta, Atlanta, GA, 4Emory University, Atlanta, GA, 5Emory University/Children's Healthcare of Atlanta, Peachtree Corners, GA, 6Emory Rollins School of Public Health Department of Global Health, Atlanta, GA, 7Emory + Children's Pediatric Institute, Atlanta, GA

    Background/Purpose: Chronic nonbacterial osteomyelitis (CNO) is an autoinflammatory bone disorder characterized by multifocal, sterile bone inflammation in childhood. Whole-body magnetic resonance imaging (WB-MRI) allows for…
  • Abstract Number: 2130 • ACR Convergence 2025

    Systemic juvenile idiopathic arthritis- Fifteen-year experience from a tertiary centre at Bristol, United Kingdom

    Ashwini Batchu Prithvi, Chaitra Govardhan, Bushra Aladaileh and Athimalaipet V Ramanan, Bristol Royal Hospital for Children, Bristol, United Kingdom

    Background/Purpose: Systemic juvenile idiopathic arthritis (sJIA) is a chronic disease that results in significant morbidity and mortality in children1. Improved understanding of the pathophysiology of…
  • Abstract Number: 1815 • ACR Convergence 2025

    New-Onset Juvenile Spondyloarthritis is Characterized by Bone Metabolism Disturbances with Biomarker Potential

    Brittney Newby1, Timothy Brandon1, Pamela Weiss2 and E. John Wherry3, 1Children's Hospital of Philadelphia, Philadelphia, PA, 2Childrens Hospital of Philadelphia, Philadelphia, PA, 3University of Pennsylvania, Philadelphia, PA

    Background/Purpose: Juvenile spondyloarthritis (JSpA) management is hindered by the lack of reliable biomarkers to predict which patients will develop progressive structural changes, such as erosions…
  • Abstract Number: 1672 • ACR Convergence 2025

    Classification criteria, disease phenotypes and long-term outcomes of childhood Sjögren’s Disease into adulthood

    Coziana Ciurtin1, Ruby Gotch2, Hannah Peckham1, Robert Wilson2, Muthana AlObaidi3 and Elizabeth C Jury1, 1University College London, London, United Kingdom, 2University College London Hospital NHS Trust, London, United Kingdom, 3Great Ormond Street Hospital, London, United Kingdom

    Background/Purpose: Childhood Sjögren Disease (cSjD) is a rare clinical phenotype lacking research on long-term outcomes and impact on the quality of life of young people…
  • Abstract Number: 1293 • ACR Convergence 2025

    Synovitis and periarticular soft tissues abnormalities in childhood-onset systemic lupus erythematosus: an ultrasonography study

    Marianna Freire1, Jean Paulo Veronese de Souza1, Ana Renata Oliveira1, Renata Kobayasi2, Vitor Paula3, Clovis Artur Silva4 and Lucia Maria Campos5, 1Pediatric Rheumatology Unit, Instituto da Criança e do Adolescente, Hospital das Clínicas HCFMUSP, São Paulo, Sao Paulo, Sao Paulo, Brazil, 2Centro de Desenvolvimento de Educação Médica do Hospital das Clínicas HCFMUSP, São Paulo, Sao Paulo, Sao Paulo, Brazil, 3Pediatric Radiology Unit, Instituto da Criança e do Adolescente, Hospital das Clínicas HCFMUSP, São Paulo, Sao Paulo, Sao Paulo, Brazil, 4University of São Paulo, São Paulo, São Paulo, Brazil, 5Instituto da Criança e do Adolescente, São Paulo, São Paulo, Brazil

    Background/Purpose: Musculoskeletal (MSK) involvement occurs in up to 70% of childhood-onset systemic lupus erythematosus (cSLE). MSK ultrasound (US) has emerged as a tool with greater…
  • Abstract Number: 1277 • ACR Convergence 2025

    Combination Therapy with Rituximab and Cyclophosphamide for Treating Pediatric Patients with Severe Manifestations of Rheumatic Disease

    Eileen Rife1, Daniel Reiff2, John Bridges3, Emily Smitherman1, randy Cron1, Matthew Stoll1, Melissa Mannion1, Peter Weiser4 and Livie Timmerman5, 1University of Alabama at Birmingham, birmingham, AL, 2Boys Town Hospital, Omaha, 3University of Alabama at Birmingham/Children's of Alabama, Birmingham, AL, 4University of Alabama at Birmingham, Birmingham, 5University of Alabama at Birmingham, Gardendale, AL

    Background/Purpose: Current practice guidelines recommend either rituximab (RTX) or cyclophosphamide (CYC) for treatment of organ-threatening manifestations of systemic vasculitis or connective tissue disease (e.g., diffuse…
  • Abstract Number: 0427 • ACR Convergence 2025

    Maternal Smoking During Pregnancy and Risk of Juvenile Idiopathic Arthritis (JIA): Triangulating Evidence from Polygenic Risk Scores and Meta-Analysis in Scandinavian Birth Cohorts

    Vilde Øverlien Dåstøl1, Kristine Løkås Haftorn2, Maria Christine Magnus3, Sigrid Hestetun4, Siri Eldevik Håberg5, Lisa Rider6, Karen H. Costenbader7, Ida Henriette Caspersen8, Sjurdur Frodi Olsen9, Ketil Størdal10 and Helga Sanner1, 1Oslo University Hospital, Oslo, Norway, 2Oslo University Hospital, Department of Rheumatology, Oslo, Norway, 3Norwegian Institute of Public Health, Centre for Fertility and Health, Oslo, Norway, 4Oslo University Hospital, Department of Rheumatology/University of Oslo, Oslo, Norway, 5Norwegian Institute of Public Health, Centre for Fertility and Health/University of Bergen, Oslo, Norway, 6National Institute of Environmental Health Sciences/National Institutes of Health, Environmental Autoimmunity Group, Bethesda, MD, 7Harvard Medical School and Brigham and Women's Hospital, Boston, MA, 8Norwegian Institute of Public Health, Centre for Fertility and Health/Oslo University Hospital, Oslo, Norway, 9Statens Serum Institut,Biobank, congenital disorders, and vaccines preparedness/Harvard T.H. Chan School of Public Health, Copenhagen, Denmark, 10Oslo University Hospital, Department of Pediatric and Adolescent Medicine/University of Oslo, Oslo, Norway

    Background/Purpose: Maternal smoking during pregnancy has been associated with a seemingly lower risk of juvenile idiopathic arthritis (JIA) in the child (1), contrasting with smoking’s…
  • Abstract Number: 0401 • ACR Convergence 2025

    Longitudinal Effectiveness of Abatacept in JIA: Results From an Ongoing JIA Registry

    Daniel Lovell1, Nicolino Ruperto2, Jennifer Huggins3, Ekaterina Alexeeva4, Colleen Correll5, John Bohnsack6, Stacey Tarvin7, Gabriele Simonini8, Thomas Griffin9, Andrew Zeft10, Gerd Horneff11, Pierre Quartier12, Iionka Orban13, Heather Walters14, Valda Stanevica15, Julisa Patel16, Adam M Huber17, Margalit Rosenkranz18, Daniel Kingsbury19, Rosie Scuccimarri20, Gabriel Vega Cornejo21, Joost Swart22, Robert Carroll23, Hermine Brunner1, Tina Sherrard24, Chiara Pallotti25, Clara Malattia26 and Alberto Martini26, 1Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 2Università degli Studi Milano-Bicocca, Milan, Italy, 3Cincinnati Children's Medical Center, Cincinnati, OH, 4National Medical Research Center for Children’s Health Federal State Autonomous Institution of the Russian Federation Ministry of Health and I.M. Sechenov First Moscow State Medical University (Sechenovskiy University), Moscow, Russia, 5University of Minnesota, Minneapolis, MN, 6University of Utah, Salt Lake City, UT, 7Riley Hospital for Children at Indiana University, Indianapolis, IN, 8Rheumatology Unit, ERN-ReCONNET center, Meyer Children's Hospital IRCCS, Firenze, Firenze, Italy, 9Atrium Health Levine Children’s Hospital, Charlotte, NC, 10Cleveland Clinic, Cleveland, OH, 11Asklepios Klinik, Hamburg, Germany, 12Hôpital Necker-Enfants Malades, Paris, France, 13Department of Rheumatology and Clinical Immunology of Semmelweis University, Budapest, Hungary, 14Northwell, New Hyde Park, NY, 15Riga Stradiņš University, Riga, Latvia, 16Children’s Hospital of Georgia, Augusta University, Augusta, GA, 17IWK Grace Health Centre, Halifax, NS, Canada, 18University of Pittsburgh, Pittsburgh, PA, 19Randall Children’s Hospital at Legacy Emanuel, Portland, OR, 20McGill University Health Centre, Montreal, QC, Canada, 21Clinica de reumatología Guadalajara, Guadalajara, Jalisco, Mexico, 22Wilhelmina Children's Hospital / UMC Utrecht, Utrecht, Utrecht, Netherlands, 23Bristol Myers Squibb, London, United Kingdom, 24Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 25Istituto G. Gaslini, Servizio di Sperimentazioni Cliniche Pediatriche, Genova, Italy, 26Istituto G. Gaslini Pediatria II Reumatologia and University of Genova, Genova, Italy

    Background/Purpose: Abatacept is a selective T-cell co-stimulation modulator approved for use in JIA. Efficacy and safety of abatacept in patients (pts) with JIA have been…
  • Abstract Number: 0119 • ACR Convergence 2025

    Thrombin Generation Assays Inform Hypercoagulability Mediated by Antiphospholipid Antibodies in Children with Systemic Lupus Erythematosus

    Elizabeth Sloan1, Blake Baay2, Lynnette Walters2, Paola Sparagana2, Kristina Ciaglia1, Simrat Morris1, Julie Fuller1, Lorien Nassi1, Tracey Wright1 and Ayesha Zia3, 1UT Southwestern, Children's Medical Center, and Scottish Rite for Children, Dallas, TX, 2Scottish Rite for Children, Dallas, TX, 3UT Southwestern and Children's Medical Center, Dallas, TX

    Background/Purpose: In pediatric systemic lupus erythematosus (SLE), antiphospholipid antibodies (aPL) are independent risk factors for thrombosis. However, data are limited on how aPL impact hypercoagulability.…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • …
  • 62
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology